The VDZ-CDST scoring system has been developed and tested through post hoc analyses using data from over 2400 patients across multiple cohorts from studies conducted globally.1–7 It is supported by peer-reviewed data with 4 publications and 3 main abstracts covering different clinical endpoints.
Click on the links below to access all the publications and abstracts:
- Dulai et Al. (2018)1 Development and validation of a scoring system to predict outcomes of vedolizumab treatment in patients with Crohn's disease
- Dulai et al. (2021)2 Early intervention with vedolizumab and longer-term surgery rates in Crohn’s disease: Post hoc analysis of the GEMINI Phase 3 and long-term safety programmes
- Alric et al. (2022)3 Vedolizumab clinical decision support tool predicts efficacy of vedolizumab but not ustekinumab in refractory Crohn’s disease
- Dulai et al. (2022)4 Probability of response as defined by a clinical decision support tool is associated with lower healthcare resource utilisation in vedolizumab-treated patients with Crohn’s disease
- Chalakatevaki et al. (2022)5 The vedolizumab clinical decision support tool for Crohn’s disease effectively predicts clinical remission at 54 weeks in a ‘real-world’ setting
- Dulai et al. (2023)6 Application of the clinical decision support tool to predict treatment outcomes in Crohn’s disease patients treated with vedolizumab subcutaneous formulation
- Dulai et al. (2023)7 Response trajectory by the clinical decision support tool probability groups in vedolizumab-treated patients with Crohn's disease: A pooled analysis of GEMINI 2, VISIBLE 2 and VERSIFY
*Further studies are needed to determine how the VDZ-CDST scoring system in CD can be used for SC vedolizumab. CD, Crohn’s disease; CDST, clinical decision support tool; HRU, healthcare resource utilisation; IBD, inflammatory bowel disease; LTS, long-term safety; PRO, patient-reported outcome; QoL, quality of life; SC, subcutaneous; UST, ustekinumab; VDZ, vedolizumab. 1. Dulai PS, et al. Gastroenterology 2018;155:687–695; 2. Dulai PS, et al. J Crohns Colitis 2021;195–202; 3. Alric H, et al. Inflamm Bowel Dis 2022;28:218–225; 4. Dulai PS, et al. Crohns Colitis 360,XXXX,4,1-8; 5. Chalakatevaki K, et al. United Eur Gastroenterol J 2022;10(8 suppl):797–798; 6. Dulai PS, et al. J Crohns Colitis 2023;17(1 suppl):i490–i491; 7. Dulai PS, et al. Am J Gastroenterol 118(10S):p S670 – S671, October 2023; 8. Borg-Bartolo SP, et al. F1000Res 2020; 9: 54; 9. Vieujean S, et al. Therap Adv Gastroenterol. 2023, Vol.16: 1-52.
C-APROM/BBE/ENTY/0261 - Aug 2024